DE60141742D1 - Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten - Google Patents

Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten

Info

Publication number: DE60141742D1
Authority: DE; Germany
Prior art keywords: free; harnic; aggregate; acid oxidase; preparing non
Prior art date: 2000-02-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60141742T

Other languages

English (en)

Inventor

Merry R Sherman

Mark G Saifer

David L Williams

Michael S Hershfield

Susan J Kelly

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mountain View Pharmaceuticals Inc

Duke University

Original Assignee

Mountain View Pharmaceuticals Inc

Duke University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-10

Filing date

2001-02-07

Publication date

2010-05-20

2001-02-07 Application filed by Mountain View Pharmaceuticals Inc, Duke University filed Critical Mountain View Pharmaceuticals Inc

2010-05-20 Application granted granted Critical

2010-05-20 Publication of DE60141742D1 publication Critical patent/DE60141742D1/de

2021-02-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

DE60141742T 2000-02-10 2001-02-07 Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten Expired - Lifetime DE60141742D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/501,730 US6783965B1 (en)	2000-02-10	2000-02-10	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PCT/US2001/040069 WO2001059078A2 (en)	2000-02-10	2001-02-07	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Publications (1)

Publication Number	Publication Date
DE60141742D1 true DE60141742D1 (de)	2010-05-20

Family

ID=23994789

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60141742T Expired - Lifetime DE60141742D1 (de)	2000-02-10	2001-02-07	Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten

Country Status (28)

Country	Link
US (3)	US6783965B1 (de)
EP (3)	EP2305819B1 (de)
JP (2)	JP5165826B2 (de)
KR (3)	KR100884724B1 (de)
CN (2)	CN101735991B (de)
AT (1)	ATE463576T1 (de)
AU (3)	AU2001249975B2 (de)
BE (1)	BE2013C045I2 (de)
BR (1)	BRPI0108386B8 (de)
CA (1)	CA2398679C (de)
CY (3)	CY1110142T1 (de)
CZ (1)	CZ304864B6 (de)
DE (1)	DE60141742D1 (de)
DK (3)	DK1254237T3 (de)
ES (2)	ES2343105T3 (de)
FR (1)	FR13C0036I2 (de)
HK (4)	HK1056742A1 (de)
HU (1)	HU227127B1 (de)
IL (3)	IL151065A0 (de)
LU (1)	LU92237I2 (de)
MX (1)	MXPA02007545A (de)
NZ (1)	NZ520434A (de)
PL (1)	PL208064B1 (de)
PT (2)	PT2305819E (de)
RU (3)	RU2281954C2 (de)
TW (2)	TW200914617A (de)
WO (1)	WO2001059078A2 (de)
ZA (1)	ZA200207206B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
RU2246318C2 (ru) *	1998-08-06	2005-02-20	Маунтэн Вью Фармасьютикэлз, Инк.	Конъюгаты peg-уриказы и их использование
US6783965B1 (en)	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT1588716E (pt) *	1998-08-06	2011-05-25	Mountain View Pharmaceuticals	Conjugados de peg-urato oxidase e sua utiliza??o
US20060188971A1 (en) *	1998-08-06	2006-08-24	Duke University	Urate oxidase
WO2000008196A2 (en)	1998-08-06	2000-02-17	Duke University	Urate oxidase
EP1421175B1 (de)	2001-06-28	2008-11-19	Mountain View Pharmaceuticals, Inc.	Polymerstabilisierte proteinasen
US6913915B2 (en)	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
DK1941867T3 (da)	2002-06-07	2012-01-02	Dyax Corp	Polypeptid med modificeret Kunitz domæne
US8129330B2 (en) *	2002-09-30	2012-03-06	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en)	2002-09-30	2004-04-01	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
NZ541124A (en) *	2002-12-26	2008-08-29	Mountain View Pharmaceuticals	Polymer conjugates of interferon-beta with enhanced biological potency
MXPA05012315A (es) *	2003-05-12	2006-04-18	Affymax Inc	Compuestos poli(etilenglicol) modificados novedosos y usos de los mismos.
WO2004100997A2 (en) *	2003-05-12	2004-11-25	Affymax, Inc.	Spacer moiety for poly(ethylene glycol) -modified peptides
KR101227666B1 (ko) *	2003-05-12	2013-01-31	아피맥스, 인크.	에리스로포이에틴 수용체에 결합하는 펩티드
PT1663281E (pt) *	2003-08-29	2014-03-17	Dyax Corp	Inibidores de proteases poli-peguilados
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EA200700990A1 (ru) *	2004-11-11	2008-04-28	Афимакс, Инк.	Новые пептиды, которые связывают рецептор эритропоэтина
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
EP1868652A2 (de) *	2005-04-05	2007-12-26	Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.	Verfahren zur abschirmung von funktionalen stellen oder epitopen auf proteinen
US20080159976A1 (en) *	2005-04-11	2008-07-03	Jacob Hartman	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US7811800B2 (en)	2005-04-11	2010-10-12	Savient Pharmaceuticals, Inc.	Variant form of urate oxidase and use thereof
US8148123B2 (en) *	2005-04-11	2012-04-03	Savient Pharmaceuticals, Inc.	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
JP2008535500A (ja)	2005-04-11	2008-09-04	サビエントファーマセウティカルズインク．	変異型尿酸オキシダーゼおよびその利用
US20090081122A1 (en) *	2005-05-23	2009-03-26	Universite De Geneve	Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US7550433B2 (en) *	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
CN101622270B (zh) *	2006-04-12	2014-01-01	萨文特医药公司	用阳离子表面活性剂纯化蛋白质的方法
WO2009026334A2 (en) *	2007-08-21	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
AU2010203712A1 (en)	2009-01-06	2010-07-15	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
SG176897A1 (en)	2009-06-25	2012-01-30	Savient Pharmaceuticals Inc	Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2011085103A2 (en)	2010-01-06	2011-07-14	Dyax Corp.	Plasma kallikrein binding proteins
WO2011127393A2 (en)	2010-04-08	2011-10-13	Georgia Tech Research Corporation	Variants of ancestral uricases and uses thereof
JP2014506257A (ja)	2011-01-06	2014-03-13	ダイアックスコーポレーション	血漿カリクレイン結合タンパク質
CN102827073A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
WO2014197806A2 (en)	2013-06-07	2014-12-11	Allena Pharmaceuticals, Inc.	Compositions, methods, and devices for dialysis
JP6529492B2 (ja)	2013-07-11	2019-06-12	アジオスファーマシューティカルズ，インコーポレイテッド	癌の処置のためのｉｄｈ２突然変異体阻害剤としての２，４−または４，６−ジアミノピリミジン化合物
US9579324B2 (en)	2013-07-11	2017-02-28	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
WO2015003360A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
WO2015003355A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
US20150031627A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
AU2015229214B2 (en)	2014-03-14	2019-07-11	Les Laboratoires Servier	Pharmaceutical compositions of therapeutically active compounds
AU2015235967B2 (en)	2014-03-27	2020-10-22	Takeda Pharmaceutical Company Limited	Compositions and methods for treatment of diabetic macular edema
AU2016265677B2 (en)	2015-05-15	2021-12-09	Medimmune, Llc	Improved uricase sequences and methods of treatment
CA3216701A1 (en)	2015-10-15	2017-04-20	Les Laboratoires Servier	Combination therapy for treating malignancies
BR112018007656A2 (pt)	2015-10-15	2018-11-06	Agios Pharmaceuticals Inc	terapia de combinação para tratamento de doenças malignas
US11286307B2 (en)	2015-12-11	2022-03-29	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN116637177A (zh)	2016-11-11	2023-08-25	好利恩治疗美国公司	泼尼松和尿酸酶分子的组合疗法及其用途
CN111373034A (zh)	2017-07-07	2020-07-03	艾乐娜制药有限公司	重组尿酸酶
US20190309269A1 (en)	2018-03-20	2019-10-10	Rubius Therapeutics, Inc.	Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
CN109055260B (zh) *	2018-08-08	2021-11-09	淮海工学院	弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
CN114181917B (zh) *	2022-02-14	2022-06-03	潍坊华卓生物科技有限公司	一种改造尿酸酶、基因序列、制备方法及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE279486C (de)
US3616231A (en)	1968-11-14	1971-10-26	Boehringer Mannheim Gmbh	Process for the production of uricase
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS5599189A (en)	1979-01-22	1980-07-28	Mihama Hisaharu	Modified uricase free from antigenicity and its preparation
JPS55135590A (en)	1979-04-05	1980-10-22	Mihama Hisaharu	Modified asparaginase and uricase and their preparation
CH651308A5 (de)	1980-07-01	1985-09-13	Hoffmann La Roche	Interferone und deren herstellung.
JPS57192435A (en)	1981-05-20	1982-11-26	Toyobo Co Ltd	Modified polypeptide
DE3126759A1 (de)	1981-07-07	1983-01-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) *	1985-06-26	1987-01-15	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) *	1985-07-29	1989-07-11	Schering Corporation	Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de)	1986-03-10	1990-06-06	Akad Wissenschaften Ddr	Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) *	1986-04-23	1987-03-10	Mihama Hisaharu	修飾ウリカ−ゼ
JPH085506B2 (ja) *	1986-08-25	1996-01-24	日東製器株式会社	缶容器
DD279489A1 (de)	1986-12-11	1990-06-06	Leuna Werke Veb	Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) *	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en)	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
US5955336A (en) *	1988-08-17	1999-09-21	Toyo Boseki Kabushiki Kaisha	DNA sequence for uricase and manufacturing process of uricase
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) *	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
NZ234453A (en) *	1989-07-13	1993-01-27	Sanofi Sa	Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en)	1989-07-13	1995-01-17	Sanofi	Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en)	1989-08-07	1994-02-15	Debiopharm, S.A.	Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja)	1989-11-01	1991-06-25	Sumitomo Pharmaceut Co Ltd	修飾ペプチドおよびその製造方法
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US5653974A (en)	1990-10-18	1997-08-05	Board Of Regents,The University Of Texas System	Preparation and characterization of liposomal formulations of tumor necrosis factor
ES2199935T3 (es) *	1991-03-15	2004-03-01	Amgen Inc.	Pegilacion de polipeptidos.
CA2112674C (en)	1991-07-02	2005-10-04	John S. Patton	Method and device for delivering aerosolized medicaments
AU6240494A (en)	1993-02-16	1994-09-14	Enzon, Inc.	Ribosome inactivating protein compositions having reduced antigenicity
WO1994023740A1 (en) *	1993-04-22	1994-10-27	Celtrix Pharmaceuticals, Inc.	Conjugates of growth factor and bone resorption inhibitor
AU7113594A (en)	1993-06-21	1995-01-17	Enzon, Inc.	Site specific synthesis of conjugated peptides
IT1265101B1 (it) *	1993-07-23	1996-10-30	Erba Carlo Spa	Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5919455A (en)	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5711944A (en) *	1993-11-10	1998-01-27	Enzon, Inc.	Interferon polymer conjugates
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
CA2206852A1 (en) *	1994-12-07	1996-06-13	Novo Nordisk A/S	Polypeptide with reduced allergenicity
US5932462A (en) *	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) *	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	インターフェロンを含む液体製剤
FR2733914B1 (fr) *	1995-05-11	1997-08-01	Sanofi Sa	Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en)	1995-06-07	1998-12-29	Chiron Corporation	Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja)	1995-12-05	1997-06-17	Asahi Chem Ind Co Ltd	ウリカーゼを生産する実質上純粋な微生物
ES2275300T3 (es)	1997-01-15	2007-06-01	Phoenix Pharmacologics, Inc.	Factor de necrosis tumoral modificado.
DK1084136T3 (da) *	1998-06-01	2005-01-03	Genentech Inc	Adskillelse af monomere af et antistof fra dets multimere ved anvendelse af ionbytterchromatografi
RU2246318C2 (ru)	1998-08-06	2005-02-20	Маунтэн Вью Фармасьютикэлз, Инк.	Конъюгаты peg-уриказы и их использование
PT1588716E (pt)	1998-08-06	2011-05-25	Mountain View Pharmaceuticals	Conjugados de peg-urato oxidase e sua utiliza??o
US6783965B1 (en)	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2000008196A2 (en)	1998-08-06	2000-02-17	Duke University	Urate oxidase
US6425448B1 (en)	2001-01-30	2002-07-30	Cdx Gas, L.L.P.	Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) *	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
KR20160012187A (ko)	2013-05-24	2016-02-02	첸트룸 미크로엘렉트로닉 드레스덴 악치엔게젤샤프트	비 pwm 디지털 dc-dc 변환기

2000
- 2000-02-10 US US09/501,730 patent/US6783965B1/en not_active Expired - Lifetime
2001
- 2001-02-06 TW TW097145974A patent/TW200914617A/zh unknown
- 2001-02-06 TW TW090102540A patent/TWI322184B/zh not_active IP Right Cessation
- 2001-02-07 PL PL358539A patent/PL208064B1/pl unknown
- 2001-02-07 RU RU2002120486/13A patent/RU2281954C2/ru not_active IP Right Cessation
- 2001-02-07 KR KR1020027010189A patent/KR100884724B1/ko active IP Right Grant
- 2001-02-07 DK DK01923265.1T patent/DK1254237T3/da active
- 2001-02-07 CZ CZ2002-2982A patent/CZ304864B6/cs not_active IP Right Cessation
- 2001-02-07 DE DE60141742T patent/DE60141742D1/de not_active Expired - Lifetime
- 2001-02-07 ES ES01923265T patent/ES2343105T3/es not_active Expired - Lifetime
- 2001-02-07 NZ NZ520434A patent/NZ520434A/en not_active IP Right Cessation
- 2001-02-07 MX MXPA02007545A patent/MXPA02007545A/es active IP Right Grant
- 2001-02-07 EP EP10180428.4A patent/EP2305819B1/de not_active Expired - Lifetime
- 2001-02-07 DK DK10180428.4T patent/DK2305819T3/en active
- 2001-02-07 AU AU2001249975A patent/AU2001249975B2/en not_active Revoked
- 2001-02-07 IL IL15106501A patent/IL151065A0/xx unknown
- 2001-02-07 EP EP01923265A patent/EP1254237B1/de not_active Expired - Lifetime
- 2001-02-07 EP EP10158016.5A patent/EP2196538B1/de not_active Expired - Lifetime
- 2001-02-07 PT PT101804284T patent/PT2305819E/pt unknown
- 2001-02-07 BR BRPI0108386A patent/BRPI0108386B8/pt not_active Application Discontinuation
- 2001-02-07 HU HU0204544A patent/HU227127B1/hu active Protection Beyond IP Right Term
- 2001-02-07 AU AU4997501A patent/AU4997501A/xx active Pending
- 2001-02-07 ES ES10180428.4T patent/ES2524153T3/es not_active Expired - Lifetime
- 2001-02-07 WO PCT/US2001/040069 patent/WO2001059078A2/en active Application Filing
- 2001-02-07 RU RU2006107110/13A patent/RU2352354C2/ru active
- 2001-02-07 KR KR1020087024272A patent/KR101054247B1/ko active IP Right Grant
- 2001-02-07 CN CN2009101278530A patent/CN101735991B/zh not_active Expired - Lifetime
- 2001-02-07 PT PT01923265T patent/PT1254237E/pt unknown
- 2001-02-07 JP JP2001558218A patent/JP5165826B2/ja not_active Expired - Lifetime
- 2001-02-07 CN CNB018077501A patent/CN100491532C/zh not_active Expired - Lifetime
- 2001-02-07 CA CA2398679A patent/CA2398679C/en not_active Expired - Lifetime
- 2001-02-07 DK DK10158016.5T patent/DK2196538T3/en active
- 2001-02-07 KR KR1020077018682A patent/KR20070092329A/ko active Search and Examination
- 2001-02-07 AT AT01923265T patent/ATE463576T1/de active
2002
- 2002-08-05 IL IL151065A patent/IL151065A/en active Protection Beyond IP Right Term
- 2002-09-09 ZA ZA200207206A patent/ZA200207206B/en unknown
2003
- 2003-12-11 HK HK03109064.9A patent/HK1056742A1/xx not_active IP Right Cessation
2007
- 2007-08-03 US US11/882,750 patent/US7927852B2/en not_active Expired - Fee Related
2008
- 2008-08-11 IL IL193365A patent/IL193365A/en active IP Right Grant
2009
- 2009-02-06 RU RU2009104003/10A patent/RU2557318C9/ru active
- 2009-09-02 AU AU2009212900A patent/AU2009212900B2/en not_active Expired
2010
- 2010-06-29 CY CY20101100597T patent/CY1110142T1/el unknown
- 2010-10-27 HK HK10110105.9A patent/HK1143989A1/xx not_active IP Right Cessation
- 2010-10-27 HK HK11109405.7A patent/HK1155203A1/xx not_active IP Right Cessation
- 2010-12-08 HK HK10111402.7A patent/HK1144701A1/xx not_active IP Right Cessation
2011
- 2011-04-12 JP JP2011088663A patent/JP5341945B2/ja not_active Expired - Lifetime
- 2011-04-13 US US13/085,793 patent/US8921064B2/en not_active Expired - Fee Related
2013
- 2013-07-03 LU LU92237C patent/LU92237I2/fr unknown
- 2013-07-03 BE BE2013C045C patent/BE2013C045I2/fr unknown
- 2013-07-04 FR FR13C0036C patent/FR13C0036I2/fr active Active
- 2013-07-04 CY CY2013028C patent/CY2013028I2/el unknown
2015
- 2015-02-09 CY CY20151100129T patent/CY1117264T1/el unknown

Also Published As

Publication number	Publication date
CN101735991B (zh)	2013-09-11
CY1117264T1 (el)	2017-04-26
CZ20022982A3 (cs)	2003-01-15
EP2196538A1 (de)	2010-06-16
EP2305819B1 (de)	2014-11-12
CN101735991A (zh)	2010-06-16
JP2003521937A (ja)	2003-07-22
HUP0204544A2 (en)	2003-05-28
IL151065A (en)	2008-12-29
PT2305819E (pt)	2015-06-01
AU2009212900A1 (en)	2009-10-01
BR0108386B1 (pt)	2017-10-31
ES2524153T3 (es)	2014-12-04
ATE463576T1 (de)	2010-04-15
CA2398679C (en)	2015-11-17
CN100491532C (zh)	2009-05-27
WO2001059078A3 (en)	2002-03-07
FR13C0036I2 (fr)	2014-05-16
CN1423699A (zh)	2003-06-11
TWI322184B (en)	2010-03-21
KR101054247B1 (ko)	2011-08-08
HK1143989A1 (en)	2011-01-21
US20080057048A1 (en)	2008-03-06
BR0108386C1 (pt)	2011-12-20
KR20070092329A (ko)	2007-09-12
RU2352354C2 (ru)	2009-04-20
US20110287466A1 (en)	2011-11-24
CY2013028I1 (el)	2015-11-04
HK1056742A1 (en)	2004-02-27
HU227127B1 (en)	2010-07-28
US7927852B2 (en)	2011-04-19
TW200914617A (en)	2009-04-01
JP5165826B2 (ja)	2013-03-21
BR0108386A (pt)	2002-10-29
IL151065A0 (en)	2003-04-10
LU92237I2 (fr)	2013-09-03
US6783965B1 (en)	2004-08-31
MXPA02007545A (es)	2002-12-13
CA2398679A1 (en)	2001-08-16
KR20080098686A (ko)	2008-11-11
ES2343105T8 (es)	2013-07-15
EP2305819A1 (de)	2011-04-06
IL193365A (en)	2011-08-31
PL358539A1 (en)	2004-08-09
WO2001059078A2 (en)	2001-08-16
RU2009104003A (ru)	2010-08-20
DK2196538T3 (en)	2015-01-05
IL193365A0 (en)	2009-02-11
AU2001249975B2 (en)	2006-06-08
JP2011188861A (ja)	2011-09-29
HK1144701A1 (en)	2011-03-04
RU2006107110A (ru)	2007-09-20
HK1155203A1 (en)	2012-05-11
AU4997501A (en)	2001-08-20
KR20020087934A (ko)	2002-11-23
RU2557318C2 (ru)	2015-07-20
EP1254237B1 (de)	2010-04-07
AU2009212900B2 (en)	2011-12-08
KR100884724B1 (ko)	2009-02-19
ZA200207206B (en)	2003-05-06
BRPI0108386B8 (pt)	2021-05-25
BE2013C045I2 (de)	2020-06-24
JP5341945B2 (ja)	2013-11-13
PL208064B1 (pl)	2011-03-31
CY2013028I2 (el)	2015-11-04
HUP0204544A3 (en)	2007-05-02
RU2281954C2 (ru)	2006-08-20
PT1254237E (pt)	2010-06-07
NZ520434A (en)	2004-05-28
RU2557318C9 (ru)	2015-09-10
CY1110142T1 (el)	2015-01-14
DK1254237T3 (da)	2010-07-19
FR13C0036I1 (fr)	2013-08-09
DK2305819T3 (en)	2015-01-05
CZ304864B6 (cs)	2014-12-17
EP1254237A2 (de)	2002-11-06
EP2196538B1 (de)	2014-10-01
US8921064B2 (en)	2014-12-30
ES2343105T3 (es)	2010-07-23

Legal Events

Date

Code

Title

Description

2011-04-28

8364

No opposition during term of opposition

2013-09-05

R065

Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: PEGLOTICASE SOWIE JEGLICHE THERAPEUTISCH AEQUIVALENTE VOM GRUNDPATENT GESCHUETZTE FORM DAVON; REGISTRATION NO/DATE: EU/1/12/810 20130108

Spc suppl protection certif: 122013000058

Filing date: 20130705

Expiry date: 20210208

Effective date: 20130715